Background: HER2-positive breast cancer remains an incurable disease. Resistance to HER2-directed therapies is common with many patients needing multiple lines of treatment. HER2CLIMB is a phase 3 trial that studied a small molecule tyrosine kinase inhibitor (TKI) targeted toward HER2 - tucatinib in combination with trastuzumab and capecitabine. This tr…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.